In glioma, pDCs exhibit an impaired response to TLR7/9 stimulation and are defective in T-cell immunity and type I IFN secretion, resulting in regulatory T-cell (Treg) accumulation and immunosuppressive microenvironment, which further contributes to tumor progression and poor patient survival [82]. The gene discussed is TLR7; the disease is central nervous system cancer.